Stepped Care aiTBS 2 Depression Study (Ghent)

Depressive Disorder, Major Clinical Trial

— aiTBS2-Ghent  

Official title:

The Effects of Accelerated Intermittent Thetaburst Stimulation Followed by a Cognitive Control Training in Treatment Resistant Unipolar Depressed Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03288675
• Other study ID #: BC-1812
• Status: Completed
• Phase: N/A
• Start date: October 5, 2017
• Est. completion date: December 31, 2023

Study information

• Verified date: January 2024
• Source: University Hospital, Ghent
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Antidepressant-free unipolar melancholic depressed patients (at least stage 2 treatment-resistant) will be selected by a certified psychiatrist, who will administer (semi-)structured clinical interviews. Because concomitant antidepressant treatment can confound outcome results, all patients will go through a medication washout before entering the study and they will be free from any antidepressant, neuroleptic and mood stabilizer for at least two weeks before entering the treatment protocol. Only habitual benzodiazepine agents will be allowed.

STEP 1: Patients will be treated with in total 20 accelerated intermittent Theta Burst Stimulation (aiTBS) sessions (3000 pulses/session) over the left dorsolateral prefrontal cortex, which will be spread over 4 days. On each stimulation day, a given patient will receive 5 sessions with a between-session delay of 15 minutes. Patients will be randomized to receive either the real aiTBS or sham treatment (first week). However, the sham group will receive real aiTBS treatment with 10 days' time interval. The investigators expect that real aiTBS treatment and not sham will result in a significant and clinical meaningful response.

STEP 2: To optimize treatment and reduce relapse following the iTBS treatment, in a stepped care approach, all patients then continue with cognitive control training (CCT) ten days later. This CCT consists of 20 sessions, spread over 4 weeks. Patients will be randomized to receive either real CCT or a control training. During this follow-up treatment, all patients will be prescribed antidepressant medication (SSRI) again. As iTBS treatment effects are known to decline over time, the investigators expect that combining aiTBS with a follow-up CCT therapy will stabilize the clinical effects over time compared to receiving the iTBS treatment alone.

For baseline comparisons, patients will be closely matched for gender and age with never-depressed, medication-free healthy volunteers. No volunteer will undergo treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 68
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Antidepressant-free unipolar major depression with melancholic features

• Not responding to at least two trials with an antidepressant

• Aged between 18-65 years old

Exclusion Criteria:

• Depression with bipolar/psychotic features

• Dysthymia

• Severe personality disorders

• Active substance abuse/dependence within a year prior to inclusion

• Pregnancy or without effective anticonception for the duration of the trial

• ECT non-responder

• No response to more than 9 antidepressants

• Any neurological condition

• Any implanted electronic device susceptible for magnetic field radiation (e.g. pacemaker)

• Any implanted metal device in the head region

• Current or past history of epilepsy

• Neurosurgical interventions

• Known allergic reaction to radiotracers or associated compounds

Healthy volunteers may be accepted as control subjects.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Depressive Disorder, Treatment-Resistant
• Melancholia
• Treatment Resistant Depression

Intervention

Device:
• aiTBS
In the active aiTBS arm, the patients will receive 100 cycli of thetaburst trains of 2s, separated by an inter-train-interval of 6 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC; i.e. 3000 pulses per session). On each stimulation day, a given patient will receive 5 sessions with a between-session interval of 15 minutes. The treatment protocol of in total 20 aiTBS sessions will be spread over 4 days (i.e. 60.000 pulses in total). The sham coil has been specifically developed to mimic the real one.

Behavioral:
• CCT
By training working memory processing, the CCT aims at modulating similar prefrontal cortex regions as being stimulated previously by aiTBS, namely the DLPFC. thereby possibly stabilizing clinical effects of aiTBS over time. In total 20 sessions of CCT vs. control training (of approximately 25 minutes per session), will be spread over a period of 4 weeks.

Drug:
• SSRI
All patients will be prescribed antidepressant medication (SSRI) again when starting the CCT (vs. control training).

Locations

Country	Name	City	State
Belgium	University Hospital Ghent	Ghent	East-Flanders

Sponsors (2)

Lead Sponsor	Collaborator
University Ghent	University Hospital, Ghent

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in depression severity - clinician-rated	17-item Hamilton Rating Scale for Depression (HRSD)	Intake, baseline (D0), 3 days after aiTBS or sham (+/-D7), 10 days after aiTBS or sham (+/-D14), [for the sham group 3 days (+/-D21) and 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up
Secondary	Changes in depression severity - self-report	Beck Depression Inventory (BDI-II)	Intake, baseline (D0), 3 days after aiTBS or sham (+/-D7), 10 days after aiTBS or sham (+/-D14), [for the sham group 3 days (+/-D21) and 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up
Secondary	Changes in suicidal thoughts - clinician-rated	Scale for suicidal ideation (SSI)	Intake, baseline (D0), 3 days after aiTBS or sham (+/-D7), 10 days after aiTBS or sham (+/-D14), [for the sham group 3 days (+/-D21) and 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up
Secondary	Changes in melancholic features - clinician-rated	Clinical outcomes in routine evaluation (CORE)	Intake, baseline (D0), 3 days after aiTBS or sham (+/-D7), 10 days after aiTBS or sham (+/-D14), [for the sham group 3 days (+/-D21) and 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up
Secondary	Changes in hopelessness - self-report	Beck hopelessness scale (BHS)	Baseline (D0), 3 days after aiTBS or sham (+/-D7), 10 days after aiTBS or sham (+/-D14), [for the sham group 3 days (+/-D21) and 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up
Secondary	Changes in anxiety features - self-report	State/Trait Anxiety Inventory (STAI)	Baseline (D0), 3 days after aiTBS or sham (+/-D7), 10 days after aiTBS or sham (+/-D14), [for the sham group 3 days (+/-D21) and 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up
Secondary	Changes in remission from depression - self-report	Remission from Depression Questionnaire (RDQ)	Baseline (D0), 3 days after aiTBS or sham (+/-D7), 10 days after aiTBS or sham (+/-D14), [for the sham group 3 days (+/-D21) and 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up
Secondary	Changes in ruminative thinking (trait) - self-report	Ruminative Responses Scale (RRS)	Baseline (D0), 10 days after aiTBS or sham (+/-D14), [for the sham group 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up
Secondary	Changes in hedonia - self-report	Temporal Experience of Pleasure Scale (TEPS)	Baseline (D0), 10 days after aiTBS or sham (+/-D14), [for the sham group 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up
Secondary	Changes in anhedonia - self-report	Snaith-Hamilton Pleasure Scale (SHAPS)	Baseline (D0), 10 days after aiTBS or sham (+/-D14), [for the sham group 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up
Secondary	Changes in perceived stress - self-report	Perceived Stress Scale (PSS)	Baseline (D0), 10 days after aiTBS or sham (+/-D14), [for the sham group 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up
Secondary	Changes in responses to positive affect - self-report	Responses to Positive Affect Scale (RPA)	Baseline (D0), 10 days after aiTBS or sham (+/-D14), [for the sham group 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up
Secondary	Changes in cognitive emotion regulation - self-report	Cognitive Emotion Regulation Questionnaire (CERQ)	Baseline (D0), 10 days after aiTBS or sham (+/-D14), [for the sham group 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up
Secondary	Changes in temperament and character - self-report	Temperament and Character Inventory (TCI)	Intake, 10 days after aiTBS or sham (+/-D14)
Secondary	Differences in adverse effects following aiTBS vs. sham - self-report	Adverse effects questionnaire	10 days after aiTBS or sham (+/-D14), [for the sham group 10 days after active aiTBS (+/-D28)]
Secondary	Changes in regional grey matter volume using structural MRI	The analysis will be done using voxel-based morphometry	Baseline (D0), 10 days after aiTBS or sham (+/-D14)
Secondary	Changes in regional white matter microstructure and structural connectivity	The analysis will be done using diffusion tensor imaging (DTI)	Baseline (D0), 10 days after aiTBS or sham (+/-D14)
Secondary	Neuronal safety/ changes in neurometabolite concentrations in left-prefrontal tissues using MRS	The analysis will be evaluated using 1H MR spectroscopy	Baseline (D0), 10 days after aiTBS or sham (+/-D14)
Secondary	Changes in functional activity connectivity at rest and during tasks in which self-referential social evaluations are presented via headphones in the scanner	The analysis will be evaluated using resting state and task fMRI	Baseline (D0), 10 days after aiTBS or sham (+/-D14)
Secondary	Changes in state-dependent ruminative thinking due to hearing self-referential social evaluations presented via headphones in the scanner - self-report	Before entering the scanner, and following each resting state fMRI (i.e. before hearing self-referential social evaluations and after hearing these evaluations), perseverative thinking will be assessed using the perseverative thinking questionnaire (PTQ).	Baseline (D0), 10 days after aiTBS or sham (+/-D14)
Secondary	Changes in state-dependent mood due to hearing self-referential social evaluations presented via headphones in the scanner - self-report	Before entering the scanner, and following each resting state fMRI (i.e. before hearing self-referential social evaluations and after hearing these evaluations), mood will be assessed using visual analogue scales (VAS).	Baseline (D0), 10 days after aiTBS or sham (+/-D14)
Secondary	Changes in the regional 5-HT transporter system	C11 DASB PET	Baseline (D0), 3 days after aiTBS or sham (+/-D7), 10 days after aiTBS or sham (+/-D14)
Secondary	Changes in reward processing as measured with EEG /ERP	128 channel EEG during doors gambling task to assess effects on reward processing.	Baseline (D0), 10 days after active aiTBS in both groups (+/-D14 for the active group, +/-D28 for the sham group)
Secondary	Evaluation of cognitive side-effects following iTBS vs. sham using the CANTAB battery	CANTAB battery administration (i.e. motor screening, delayed matching to sample, rapid visual information processing, one touch stockings of Cambridge, spatial working memory).	Baseline (D0), 3 days after aiTBS or sham (+/-D7)
Secondary	Changes in reward processing - behavioral assessment	Cambridge Gambling Task (CGT; CANTAB battery)	Baseline (D0), 10 days after aiTBS or sham (+/-D14), [for the sham group 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56)
Secondary	Changes in working memory - behavioral assessment of near transfer	Non-adaptive PASAT (naPASAT)	Baseline (D0), 10 days after active aiTBS in both groups (+/-D14 for the active group, +/-D28 for the sham group), after CCT (+/-D42; for the sham group +/-D56)
Secondary	Changes in state-dependent mood - self-report following naPASAT	Visual analogue scales (VAS) administered following completion of the naPASAT	Baseline (D0), 10 days after active aiTBS in both groups (+/-D14 for the active group, +/-D28 for the sham group), after CCT (+/-D42; for the sham group +/-D56)
Secondary	Changes in spatial working memory - behavioral assessment of far transfer	Spatial working memory (SWT; CANTAB battery)	Baseline (D0), 10 days after active aiTBS in both groups (+/-D14 for the active group, +/-D28 for the sham group), after CCT (+/-D42; for the sham group +/-D56)
Secondary	Changes in state-dependent mood during CCT vs. control training	Visual analogue scales (VAS) administered following completion of the CCT (or control training)	Following each of the 20 CCT or control trainings (spread over +/- D15 up to D42 for the active group; spread over +/- D29 up to D56 for the sham group)
Secondary	Predictive influence of single nucleotide polymorphisms on treatment outcome - genetics using a saliva sample	SNP analysis	At baseline (D0)
Secondary	Predictive influence of treatment expectancy on treatment response - self-report	Credibility and Expectancy Questionnaire (CEQ)	After the first aiTBS or sham session (D1), after the first CCT or control session (+/- D15 for the active group, +/-D29 for the sham group)